GamaMabs Pharma strengthens its governance with the appointment of Martine J George, M.D., as independent board member

With over 20 years experience in clinical research, Dr. George joins at a crucial time for the company

Toulouse and Paris, France, May 3, 2016  GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies for the treatment of cancer, today announces the appointment of Martine J George, M.D. as an independent board member.

Based in the US, Dr. Martine George has wide experience in developing and registering drugs in oncology – including gynecological cancers – as well as clinical research, medical and regulatory affairs.

In her last executive position, Dr. George was Vice President Global Medical Affairs, Oncology at Pfizer. Previous roles include Chief Medical Officer at GPC Biotech and Senior Vice President, Head of Oncology at Johnson & Johnson.

Dr. George is a board-certified medical oncologist and gynecologist, trained in France and Montréal (Canada). She began her career as a clinician; as head of the gynecological outpatient clinic service at the Institut Gustave Roussy near Paris, France, and visiting professor at Memorial Sloan Kettering Cancer Center in New York. Throughout her high-profile career she led the successful launch of drugs in multiple oncology indications, including ovarian cancer.

“Based on my global drug development experience and the positions I have had on various company boards, I intend to take on a dynamic role at GamaMabs Pharma and contribute to the further success of the company,” said Dr. George, discussing her new appointment. “The technology that is currently being developed by GamaMabs Pharma has the potential to transform gynecological cancer treatment and I am looking forward to being part of a leading team.”

“We are delighted to welcome Martine to the board of directors,” said Thierry Hercend, chairman of the board at GamaMabs Pharma. “This is a pivotal year for GamaMabs Pharma, after it secured a new €15m ($15.9m) financing round at the end of 2015 to advance our lead product candidate, GM102, to the clinical stage in gynecological cancers. We have high expectations for this first-in-class antibody.”

“It is a real honor to welcome Dr. George to GamaMabs’ board. Martine’s medical and business expertise is highly regarded in the industry and her joining us is a strong and positive signal for the company,” said Stéphane Degove, CEO of GamaMabs Pharma.

About GamaMabs Pharma

GamaMabs Pharma is a French biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs Pharma lead project is the first-in-class monoclonal antibody (mAb), GM102, currently entering the clinical stage, which targets the anti-Mullerian human receptor II (AMHRII/MISRII) in gynecological cancers. Ovarian cancer is responsible for over 50,000 deaths every year in Europe and the United States (Source: Globoscan 2012/WHO). The company also develops additional low-fucose EMABling® antibodies (license granted by LFB) with increased tumor cell killing properties through the activation of immune system cells.

www.gamamabs.com

Media and analyst contacts
Andrew Lloyd & Associates

Agnes Stephens – Sandra Régnavaque

agnes@ala.com – sandra@ala.com
Tel: +44 1273 675 100

US: + 1 617 202 4491
@ALA_Group